GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 25 - 80 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of ALT
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Altimmune, Inc. stock price down 2.13% on Thursday
(Updated on Apr 18, 2024)

Sell candidate since Apr 02, 2024 Loss -26.35% PDF

The Altimmune, Inc. stock price fell by -2.13% on the last day (Thursday, 18th Apr 2024) from $7.04 to $6.89. It has now fallen 5 days in a row. During the last trading day the stock fluctuated 5.84% from a day low at $6.85 to a day high of $7.25. The price has fallen in 8 of the last 10 days and is down by -22.58% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -375 thousand shares and in total, 3 million shares were bought and sold for approximately $22.05 million.

Given the current short-term trend, the stock is expected to fall -11.35% during the next 3 months and, with a 90% probability hold a price between $6.11 and $11.40 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

ALT Signals & Forecast

There are few to no technical positive signals at the moment. The Altimmune, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $7.63 and $9.39. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Tuesday, February 27, 2024, and so far it has fallen -50.11%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss for Altimmune, Inc. stock

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.400 between high and low, or 5.84%. For the last week, the stock has had daily average volatility of 7.46%.

Altimmune, Inc. is oversold on RSI14 (14). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (ALT) For The Upcoming Trading Day Of Friday 19th

For the upcoming trading day on Friday, 19th we expect Altimmune, Inc. to open at $7.00, and during the day (based on 14 day Average True Range), to move between $6.14 and $7.64, which gives a possible trading interval of +/-$0.755 (+/-10.95%) up or down from last closing price. If Altimmune, Inc. takes out the full calculated possible swing range there will be an estimated 21.90% move between the lowest and the highest trading price during the day.

With no support below and resistance from accumulated volume @ $7.04, some $0.150 (2.18%) from the current price of $6.89, our system finds the risk reward not very attractive.

Is Altimmune, Inc. stock A Buy?

Altimmune, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -5.604 Strong Sell Candidate Unchanged

Predicted Opening Price for Altimmune, Inc. of Friday, April 19, 2024

Fair opening price April 19, 2024 Current price
$7.00 ( 1.55%) $6.89

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for ALT

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 7.40 7.35 %
R2 7.24 5.14 %
R1 7.15 3.77 %
Current price: 6.89
Support S1 6.84 -0.670 %
S2 6.75 -2.04 %
S3 6.60 -4.26 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 8.46 22.79 %
R2 8.40 21.92 %
R1 7.04 2.18 %
Current price 6.89
Support S1 0 .
S2 0 .
S3 0 .

ALT Dividend Payout History


# Declaration Date Ex-Date Pay Date Amount Yield
1 Jan 20, 2017 Jan 20, 2017 Sep 14, 2018 $873.01 16,018.53%

FAQ

What is the symbol for Altimmune, Inc. Stock and on which exchange is it traded?
The symbol for Altimmune, Inc. is ALT and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Altimmune, Inc. Stock?
Altimmune, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Altimmune, Inc. Stock?
Altimmune, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Altimmune, Inc. Stock.

What's the current price of Altimmune, Inc. Stock?
As of the end of day on the 2024-04-18, the price of an Altimmune, Inc. (ALT) share was $6.89.

What is the 52-week high and low for Altimmune, Inc. Stock?
The 52-week high for Altimmune, Inc. Stock is $14.84 and the 52-week low is $2.09.

What is the market capitalization of Altimmune, Inc. Stock?
As of the 2024-04-18, the market capitalization of Altimmune, Inc. is 499.103M.

When is the next earnings date for Altimmune, Inc.?
The upcoming earnings date for Altimmune, Inc. is May 09, 2024.
Click to get the best stock tips daily for free!

About Altimmune, Inc.

Altimmune. Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinica... ALT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT